Table 4.
Subgroups Analysis
| N | All-Cause Mortality HR (95% CI) P-value | P for Log Likelihood Ratio Test | Cardiovascular Disease Mortality HR (95% CI) P-value | P for Log Likelihood Ratio Test | Cancer Mortality HR (95% CI) P-value | P for Log Likelihood Ratio Test | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cutoff value, mmol/L | <1.36 | ≥1.36 | <1.28 | ≥1.28 | <1.89 | ≥1.89 | ||||
| Age | ||||||||||
| ≥65 | 2605 | 0.59 (0.41, 0.84) 0.0036 | 1.59 (1.19, 2.12) 0.0018 | <0.001 | 0.53 (0.24, 1.17) 0.1157 | 1.34 (0.77, 2.31) 0.2977 | 0.114 | 0.84 (0.48, 1.48) 0.5477 | 5.32 (2.39, 11.86) <0.0001 | 0.004 |
| <65 | 3356 | 1.06 (0.61, 1.87) 0.8301 | 1.54 (0.88, 2.71) 0.1332 | 0.443 | 2.70 (0.72, 10.15) 0.1418 | 1.09 (0.34, 3.45) 0.8883 | 0.374 | 1.06 (0.49, 2.28) 0.8832 | 0.64 (0.02, 17.98) 0.7962 | 0.779 |
| Gender | ||||||||||
| Male | 3082 | 0.72 (0.49, 1.06) 0.0997 | 2.08 (1.39, 3.12) 0.0004 | 0.002 | 0.53 (0.23, 1.22) 0.1336 | 1.90 (0.91, 3.95) 0.0853 | 0.063 | 1.04 (0.56, 1.92) 0.8956 | 8.83 (2.27, 34.29) 0.0016 | 0.025 |
| Female | 2879 | 0.46 (0.28, 0.76) 0.0021 | 1.34 (0.77, 2.31) 0.2977 | 0.114 | 1.09 (0.28, 4.31) 0.9025 | 0.89 (0.45, 1.77) 0.7405 | 0.823 | 0.59 (0.29, 1.17) 0.1314 | 2.83 (0.93, 8.62) 0.0678 | 0.066 |
| Race | ||||||||||
| Non-white | 3633 | 0.61 (0.39, 0.95) 0.0286 | 1.50 (1.07, 2.10) 0.0174 | 0.009 | 0.99 (0.33, 2.91) 0.9799 | 0.95 (0.48, 1.86) 0.8791 | 0.960 | 0.81 (0.44, 1.50) 0.5102 | 3.07 (1.15, 8.17) 0.0252 | 0.072 |
| White | 2328 | 0.66 (0.43, 1.01) 0.0546 | 1.48 (1.00, 2.19) 0.0486 | 0.022 | 0.50 (0.20, 1.26) 0.1432 | 1.53 (0.74, 3.18) 0.2530 | 0.120 | 0.83 (0.42, 1.64) 0.5849 | 5.64 (1.33, 23.90) 0.0189 | 0.056 |
| Lipid-lowering drugs | ||||||||||
| No | 3844 | 0.61 (0.40, 0.95) 0.0283 | 1.57 (1.19, 2.07) 0.0013 | 0.003 | 0.75 (0.30, 1.89) 0.5401 | 1.45 (0.82, 2.57) 0.2060 | 0.313 | 0.89 (0.52, 1.53) 0.6653 | 3.89 (1.72, 8.80) 0.0011 | 0.019 |
| Yes | 2117 | 0.60 (0.34, 1.06) 0.0783 | 0.98 (0.63, 1.53) 0.9260 | 0.265 | 0.65 (0.23, 1.88) 0.4289 | 0.65 (0.26, 1.63) 0.3559 | 0.991 | 0.70 (0.30, 1.64) 0.4178 | 3.14 (0.23, 43.43) 0.3939 | 0.373 |
| Hypoglycemic agents | ||||||||||
| No | 2980 | 0.70 (0.45, 1.10) 0.1190 | 1.55 (1.10, 2.18) 0.0120 | 0.021 | 1.02 (0.37, 2.79) 0.9760 | 0.84 (0.40, 1.74) 0.6360 | 0.796 | 1.47 (0.79, 2.74) 0.2180 | 4.48 (2.03, 9.89) <0.001 | 0.071 |
| Yes | 3569 | 0.59 (0.39, 0.90) 0.0140 | 1.38 (0.93, 2.04) 0.1080 | 0.017 | 0.45 (0.17, 1.16) 0.0969 | 1.74 (0.87, 3.45) 0.1146 | 0.059 | 0.52 (0.26, 1.03) 0.0619 | 0.39 (0.01, 21.29) 0.6440 | 0.892 |
Notes: When analyzing a subgroup variable, age, gender, body mass index, race, education level, smoking, systolic blood pressure, estimated glomerular filtration rate, glycohemoglobin, total cholesterol, comorbidities (hypertension, cardiovascular disease, and cancer), and medicine use (antihypertensive drugs, hypoglycemic agents, lipid-lowering drugs, and antiplatelet drugs) were all adjusted except the variable itself.